204 related articles for article (PubMed ID: 32029503)
21. Myosin as cofactor and substrate in fibrinolysis.
Machovich R; Ajtai K; Kolev K; Owen WG
FEBS Lett; 1997 Apr; 407(1):93-6. PubMed ID: 9141488
[TBL] [Abstract][Full Text] [Related]
22. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
Novokhatny V; Medved L; Lijnen HR; Ingham K
J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
[TBL] [Abstract][Full Text] [Related]
23. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
24. Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells.
Ellis V; Whawell SA
Blood; 1997 Sep; 90(6):2312-22. PubMed ID: 9310482
[TBL] [Abstract][Full Text] [Related]
25. Herpesviruses enhance fibrin clot lysis.
Gershom ES; Vanden Hoek AL; Meixner SC; Sutherland MR; Pryzdial EL
Thromb Haemost; 2012 Apr; 107(4):760-8. PubMed ID: 22318336
[TBL] [Abstract][Full Text] [Related]
26. Inner clot diffusion and permeation during fibrinolysis.
Diamond SL; Anand S
Biophys J; 1993 Dec; 65(6):2622-43. PubMed ID: 8312497
[TBL] [Abstract][Full Text] [Related]
27. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC
J Vasc Surg; 1997 Jan; 25(1):157-64. PubMed ID: 9013920
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor.
Shanmukhappa K; Sabla GE; Degen JL; Bezerra JA
BMC Gastroenterol; 2006 Nov; 6():40. PubMed ID: 17134505
[TBL] [Abstract][Full Text] [Related]
29. Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice.
Jögi A; Rønø B; Lund IK; Nielsen BS; Ploug M; Høyer-Hansen G; Rømer J; Lund LR
PLoS One; 2010 Sep; 5(9):e12746. PubMed ID: 20856796
[TBL] [Abstract][Full Text] [Related]
30. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Lijnen HR; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1035-45. PubMed ID: 9672063
[TBL] [Abstract][Full Text] [Related]
31. Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease.
Kwieciński J; Josefsson E; Jin T
Inflamm Res; 2011 Nov; 60(11):1021-9. PubMed ID: 21786185
[TBL] [Abstract][Full Text] [Related]
32. [Mechanism of inhibitory effect of angiostatin on plasminogen activation by its physiologic activators].
Aĭsina RB; Mukhametova LI; Prisiazhnaia NV; Gulin DA; Levashov MIu; Gershkovich KB
Bioorg Khim; 2011; 37(3):319-26. PubMed ID: 21899046
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of corneal epithelial defects: role of plasminogen activator.
Hayashi K; Berman M; Smith D; el-Ghatit A; Pease S; Kenyon KR
Curr Eye Res; 1991 May; 10(5):381-98. PubMed ID: 1909616
[TBL] [Abstract][Full Text] [Related]
34. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
35. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of plasminogen activation by polymerized ampicillin.
al-Roof Higazi A; Hermoni M; Aziza R; Mayer M
Thromb Res; 1994 Sep; 75(6):643-51. PubMed ID: 7831683
[TBL] [Abstract][Full Text] [Related]
37. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
38. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin surge-induced up-regulation of the plasminogen activators (tissue plasminogen activator and urokinase plasminogen activator) and the urokinase plasminogen activator receptor within bovine periovulatory follicular and luteal tissue.
Dow MP; Bakke LJ; Cassar CA; Peters MW; Pursley JR; Smith GW
Biol Reprod; 2002 May; 66(5):1413-21. PubMed ID: 11967205
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
